<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Acadia Pharmaceuticals Inc. — News on 6ix</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc</link>
<description>Latest news and press releases for Acadia Pharmaceuticals Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 06 May 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/acadia-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683541a478dffbe2df0e0f12.webp</url>
<title>Acadia Pharmaceuticals Inc.</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc</link>
</image>
<item>
<title>Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-reports-first-quarter-2026-financial-results-and-reaffirms-2026-financial-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-reports-first-quarter-2026-financial-results-and-reaffirms-2026-financial-guidance</guid>
<pubDate>Wed, 06 May 2026 20:05:00 GMT</pubDate>
<description>SAN DIEGO, May 06, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026.</description>
</item>
<item>
<title>Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announces-planned-year-end-retirement-of-elizabeth-hz-thompson-phd-head-of-research-and-development-following-a-distinguished-career</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announces-planned-year-end-retirement-of-elizabeth-hz-thompson-phd-head-of-research-and-development-following-a-distinguished-career</guid>
<pubDate>Thu, 30 Apr 2026 20:05:00 GMT</pubDate>
<description>SAN DIEGO, April 30, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and le</description>
</item>
<item>
<title>Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-to-present-data-at-the-2026-american-academy-of-neurology-aan-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-to-present-data-at-the-2026-american-academy-of-neurology-aan-annual-meeting</guid>
<pubDate>Fri, 17 Apr 2026 13:05:00 GMT</pubDate>
<description>SAN DIEGO, April 17, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago, IL.</description>
</item>
<item>
<title>Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-to-announce-first-quarter-2026-financial-results-on-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-to-announce-first-quarter-2026-financial-results-on-may-6-2026</guid>
<pubDate>Wed, 15 Apr 2026 20:05:00 GMT</pubDate>
<description>SAN DIEGO, April 15, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time.</description>
</item>
<item>
<title>Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announces-daybuer-stix-trofinetide-is-now-broadly-available-in-the-united-states-for-the-treatment-of-rett-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announces-daybuer-stix-trofinetide-is-now-broadly-available-in-the-united-states-for-the-treatment-of-rett-syndrome</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>-- DAYBUE STIX is a new powder formulation of trofinetide -- Recently published expert consensus recognizes trofinetide as part of the standard of care for</description>
</item>
<item>
<title>Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-to-participate-in-the-stifel-2026-virtual-cns-forum</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-to-participate-in-the-stifel-2026-virtual-cns-forum</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>SAN DIEGO, March 12, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time.</description>
</item>
<item>
<title>Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-appoints-jonathan-m-poole-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-appoints-jonathan-m-poole-to-its-board-of-directors</guid>
<pubDate>Tue, 03 Mar 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, March 03, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company’s Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities.</description>
</item>
<item>
<title>Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announces-plan-to-request-re-examination-following-negative-chmp-opinion-for-trofinetide-for-the-treatment-of-rett-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announces-plan-to-request-re-examination-following-negative-chmp-opinion-for-trofinetide-for-the-treatment-of-rett-syndrome</guid>
<pubDate>Mon, 02 Mar 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, March 02, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally adopted a negative opinion regarding the Marketing Authorization Application for trofinetide for the treatment of Rett syndrome in patients two years of age and older. Acadia has reviewed the CHMP grounds for refusal in detail and intends to request a re-examination of the o</description>
</item>
<item>
<title>Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operating-overview</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operating-overview</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>- Fourth quarter 2025 GAAP total revenues of $284 million and full year 2025 GAAP total revenues of $1.07 billion, reflecting 9% and 12% year-over-year</description>
</item>
<item>
<title>Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announce-fourth-quarter-210500714</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announce-fourth-quarter-210500714</guid>
<pubDate>Wed, 04 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, February 04, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time.</description>
</item>
<item>
<title>Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-provides-regulatory-submission-210500296</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-provides-regulatory-submission-210500296</guid>
<pubDate>Mon, 02 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, February 02, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on its Marketing Authorization Application (MAA) for trofinetide for the treatment of Rett syndrome, following its recent CHMP oral explanation. Subject to the outcome of the CHMP vote in February, Acadia intends to request a re-examination of the opinion</description>
</item>
<item>
<title>Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-provides-business-and-pipeline-updates-44th-annual-jp-morgan</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-provides-business-and-pipeline-updates-44th-annual-jp-morgan</guid>
<pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
<description>- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID® and ~$700 million for DAYBUE® - Top-line results from</description>
</item>
<item>
<title>Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-present-44th-annual-jp-morgan-healthcare-conference-january-13</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-present-44th-annual-jp-morgan-healthcare-conference-january-13</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare</description>
</item>
<item>
<title>Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announces-fda-approval-daybuer-stix-trofinetide-oral-solution</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announces-fda-approval-daybuer-stix-trofinetide-oral-solution</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>-- DAYBUE STIX provides Rett syndrome patients and caregivers with new flexibility and choice in their treatment with DAYBUE -- DAYBUE and DAYBUE STIX are</description>
</item>
<item>
<title>Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-participate-citis-2025-global-healthcare-conference-2025-11-20</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-participate-citis-2025-global-healthcare-conference-2025-11-20</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi’s 2025 Global</description>
</item>
<item>
<title>Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-reports-third-quarter-2025-financial-results-and-operating</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-reports-third-quarter-2025-financial-results-and-operating</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>- Third quarter total revenues of $278.6 million, up 11% year-over-year - Narrowing and raising high end of NUPLAZID® net product sales guidance to $685 to</description>
</item>
<item>
<title>Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-participate-upcoming-investor-conferences-2025-10-28</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-participate-upcoming-investor-conferences-2025-10-28</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS</description>
</item>
<item>
<title>Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announce-third-quarter-2025-financial-results-november-5-2025</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announce-third-quarter-2025-financial-results-november-5-2025</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>Company to host conference call and webcast on Wednesday, November 5, 2025, at 4:30 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals</description>
</item>
<item>
<title>Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-presents-clinical-data-across-multiple-therapeutic-programs</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-presents-clinical-data-across-multiple-therapeutic-programs</guid>
<pubDate>Thu, 02 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster</description>
</item>
<item>
<title>Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint</title>
<link>https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announces-phase-3-compass-pws-trial-intranasal-carbetocin-acp</link>
<guid isPermaLink="true">https://6ix.com/company/acadia-pharmaceuticals-inc/news/acadia-pharmaceuticals-announces-phase-3-compass-pws-trial-intranasal-carbetocin-acp</guid>
<pubDate>Wed, 24 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the</description>
</item>
</channel>
</rss>